RayKnowChina Research Map
Shortlist0

RecruitingIgA nephropathyN/A

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of Telitacicept in IgAN

An open trial on IgA nephropathy, registered on ClinicalTrials.gov. Led by Ruijin Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorRuijin Hospital上海交通大学医学院附属瑞金医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06654596, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Primary IgA nephropathy confirmed by renal biopsy.

    Inclusion criterion 2

  3. Received treatment with ACEI/ARB for 12 weeks before randomization, and the drug dose (within the maximum tolerated range) was stable within 4 weeks before randomization.

    Inclusion criterion 5

  4. Urine protein ≥ 0.75g/24h or 24-hour urine protein creatinine ratio (PCR) ≥ 0.6 g/g.

    Inclusion criterion 3

    eGFR ≥ 25 ml/min/1.73 m2 calculated using the CKD-EPI formula.

    Inclusion criterion 4

    Poorly controlled diabetes (glycosylated hemoglobin>8%).

    Exclusion criterion 10

  5. Active infection, such as active tuberculosis, active hepatitis, hepatitis C, herpes zoster, HIV, etc. According to the results of the five hepatitis B test: patients with positive HBsAg should be excluded; patients with negative HBsAg but positive HBcAb, regardless of whether HBsAb is positive or negative, need to test HBV-DNA to determine their situation: if HBV-DNA is positive, the patient needs to be excluded; if HBV-DNA is negative, the patient can participate in the trial.

    Exclusion criterion 5

  6. Pregnant women and breastfeeding women.

    Exclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06654596, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 18-70 years old, male or female
  • Primary IgA nephropathy confirmed by renal biopsy.
  • Urine protein ≥ 0.75g/24h or 24-hour urine protein creatinine ratio (PCR) ≥ 0.6 g/g.
  • eGFR ≥ 25 ml/min/1.73 m2 calculated using the CKD-EPI formula.
  • Received treatment with ACEI/ARB for 12 weeks before randomization, and the drug dose (within the maximum tolerated range) was stable within 4 weeks before randomization.
  • Use of SGLT2, MRA, hydroxychloroquine, and etc. remained unchanged.
  • Voluntarily participated in this study and signed the informed consent form.

Exclusion Criteria:

  • Patients with abnormal laboratory indicators (see study protocol for details).
  • Secondary IgA nephropathy such as Henoch-Schonlein purpura, SLE, cirrhosis, etc.
  • Use of systemic glucocorticoids/immunosuppressants within 3 months (such as cyclophosphamide, azathioprine, mycophenolate mofetil, leflunomide, tacrolimus, cyclosporine, tripterygium wilfordii, etc.).
  • Use of biological agents within 6 months (rituximab, etc.).
  • Active infection, such as active tuberculosis, active hepatitis, hepatitis C, herpes zoster, HIV, etc. According to the results of the five hepatitis B test: patients with positive HBsAg should be excluded; patients with negative HBsAg but positive HBcAb, regardless of whether HBsAb is positive or negative, need to test HBV-DNA to determine their situation: if HBV-DNA is positive, the patient needs to be excluded; if HBV-DNA is negative, the patient can participate in the trial.
  • COVID-19 infection within 2 weeks before randomization.
  • Live vaccine within 4 weeks before randomization.
  • History of malignant tumor within five years.
  • Uncontrolled hypertension (systolic blood pressure>140mmHg or diastolic blood pressure>90mmHg).
  • Poorly controlled diabetes (glycosylated hemoglobin>8%).
  • Pregnant women and breastfeeding women.
  • Participating in other clinical trials at the same time.
  • Surgery, chemotherapy, radiotherapy and other treatments are planned during the study.
  • Other reasons judged by researchers as unsuitable for inclusion in the study.

Quoted from ClinicalTrials.gov, NCT06654596, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06654596, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06654596